Interest Coverage Ratio: 6.33x
Is the interest coverage ratio high or low?
The interest coverage ratio of 6.33x is 28% below its 5-year average of 8.84x, near the low end of its 5-year range (3.75x–17.37x).
As of Friday, June 26, 2026. 9.51% above its 12-month average of 5.78x.
DGX Interest Coverage Ratio
Reported quarterly interest coverage; no daily interpolation.
DGX Average Interest Coverage Ratio Chart
DGX Current vs Average Interest Coverage Ratio Chart
DGX Interest Coverage Ratio Metrics
INTEREST COVERAGE RATIO
6.33x
INTEREST COVERAGE RATIO AVG TTM
5.78x
INTEREST COVERAGE RATIO AVG 3Y
6.51x
INTEREST COVERAGE RATIO AVG 5Y
8.84x
INTEREST COVERAGE RATIO AVG 10Y
7.06x
INTEREST COVERAGE RATIO AVG 15Y
6.84x
INTEREST COVERAGE RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+9.51%
CURRENT VS 3Y AVG
-2.69%
CURRENT VS 5Y AVG
-28.37%
CURRENT VS 10Y AVG
-10.25%
CURRENT VS 15Y AVG
-7.39%
CURRENT VS 20Y AVG
N/A
DGX Competitors' Interest Coverage Ratio
| NAME | MARKET CAP | INTEREST COVERAGE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Quest Diagnostics Incorporated (DGX) | $22.83B | 6.33x | 5.78x | 6.51x | 8.84x |
| BioNTech SE (BNTX)vs › | $22.76B | -45.74x | 444.02x | 1201.03x | 1201.03x |
| United Therapeutics Corporation (UTHR)vs › | $23.07B | 77.81x | 54.95x | 40.03x | 35.88x |
| Moderna, Inc. (MRNA)vs › | $23.71B | -307.40x | 531.75x | 531.75x | 531.75x |
| Labcorp Holdings Inc. (LH)vs › | $21.83B | 6.77x | 5.99x | 5.91x | 8.30x |
| Incyte Corporation (INCY)vs › | $21.48B | 553.04x | 298.73x | 269.07x | 276.66x |
| Waters Corporation (WAT)vs › | $24.57B | 12.84x | 11.03x | 12.05x | 13.28x |
| Mettler-Toledo International Inc. (MTD)vs › | $25.13B | 16.32x | 15.71x | 16.43x | 18.17x |
| STERIS plc (STE)vs › | $20.52B | 18.15x | 14.10x | 10.28x | 10.20x |
| Veeva Systems Inc. (VEEV)vs › | $25.68B | N/A | N/A | N/A | N/A |
Financial Health Indicators
Interest Coverage
6.3x
Debt/Equity
0.96
Current Ratio
1.04
Formula: Interest Coverage = EBIT / Interest Expense
Reference ranges:
- < 1.5x: EBIT is less than 1.5 times interest expense
- 1.5x - 3x: EBIT is between 1.5 and 3 times interest expense
- 3x - 5x: EBIT is between 3 and 5 times interest expense
- > 5x: EBIT is more than 5 times interest expense
Note: Interest coverage should be compared with historical interest expense, operating income, and industry capital structure.
Interest Coverage Ratio Formula & Definition
Interest Coverage = EBIT / Interest Expense
The interest coverage ratio measures operating earnings relative to interest expense.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Interest Coverage Ratio FAQ
- What is the interest coverage ratio for Quest Diagnostics Incorporated (DGX)?
- The interest coverage ratio for DGX stock is 6.33x.
- Is Quest Diagnostics Incorporated's interest coverage ratio high or low?
- The interest coverage ratio of 6.33x is 28% below its 5-year average of 8.84x, near the low end of its 5-year range (3.75x–17.37x).
- What is the TTM average interest coverage ratio for Quest Diagnostics Incorporated (DGX)?
- The TTM average interest coverage ratio for DGX stock is 5.78x.
- What is the 3Y average interest coverage ratio for Quest Diagnostics Incorporated (DGX)?
- The 3Y average interest coverage ratio for DGX stock is 6.51x.
- What is the 5Y average interest coverage ratio for Quest Diagnostics Incorporated (DGX)?
- The 5Y average interest coverage ratio for DGX stock is 8.84x.
- What is the 10Y average interest coverage ratio for Quest Diagnostics Incorporated (DGX)?
- The 10Y average interest coverage ratio for DGX stock is 7.06x.
- What is the 15Y average interest coverage ratio for Quest Diagnostics Incorporated (DGX)?
- The 15Y average interest coverage ratio for DGX stock is 6.84x.
DGX Interest Coverage Ratio History
| DATE | INTEREST COVERAGE RATIO |
|---|---|
| 2026-03-31 | 6.33x |
| 2025-12-31 | 5.84x |
| 2025-09-30 | 5.59x |
| 2025-06-30 | 6.35x |
| 2025-03-31 | 4.81x |
| 2024-12-31 | 5.01x |
| 2024-09-30 | 5.69x |
| 2024-06-30 | 7.55x |
| 2024-03-31 | 6.12x |
| 2023-12-31 | 5.80x |
| 2023-09-30 | 8.34x |
| 2023-06-30 | 8.92x |
| 2023-03-31 | 8.24x |
| 2022-12-31 | 3.75x |
| 2022-09-30 | 10.59x |
| 2022-06-30 | 10.21x |
| 2022-03-31 | 13.86x |
| 2021-12-31 | 14.11x |
| 2021-09-30 | 17.16x |
| 2021-06-30 | 14.03x |
| 2021-03-31 | 17.37x |
| 2020-12-31 | 19.88x |
| 2020-09-30 | 17.10x |
| 2020-06-30 | 6.74x |
| 2020-03-31 | 4.17x |
| 2019-12-31 | 8.25x |
| 2019-09-30 | 6.96x |
| 2019-06-30 | 6.67x |
| 2019-03-31 | 5.51x |
| 2018-12-31 | 5.12x |
| 2018-09-30 | 7.24x |
| 2018-06-30 | 7.09x |
| 2018-03-31 | 6.63x |
| 2017-12-31 | 6.90x |
| 2017-09-30 | 7.64x |
| 2017-06-30 | 8.39x |
| 2017-03-31 | 7.54x |
| 2016-12-31 | 7.67x |
| 2016-09-30 | 8.70x |
| 2016-06-30 | 12.41x |
| 2016-03-31 | 7.14x |
| 2015-12-31 | 6.64x |
| 2015-09-30 | 18.03x |
| 2015-06-30 | 8.14x |
| 2015-03-31 | 5.07x |
| 2014-12-31 | 6.12x |
| 2014-09-30 | 6.24x |
| 2014-06-30 | 6.24x |
| 2014-03-31 | 5.33x |
| 2013-12-31 | 6.92x |
| 2013-09-30 | 17.24x |
| 2013-06-30 | 7.24x |
| 2013-03-31 | 5.69x |
| 2012-12-31 | 6.63x |
| 2012-09-30 | 7.41x |
| 2012-06-30 | 7.99x |
| 2012-03-31 | 7.08x |
| 2011-12-31 | 7.43x |
| 2011-09-30 | 7.31x |
| 2011-06-30 | 6.80x |
| 2011-03-31 | 6.97x |
| 2010-12-31 | 7.77x |
| 2010-09-30 | 9.23x |
| 2010-06-30 | 9.99x |
| 2010-03-31 | 8.29x |
| 2009-12-31 | 9.43x |
| 2009-09-30 | 10.55x |
| 2009-06-30 | 9.72x |
| 2009-03-31 | 8.06x |
| 2008-06-30 | 6.57x |
About Quest Diagnostics Incorporated
Quest Diagnostics Incorporated, founded in 1967 and headquartered in Secaucus, New Jersey, is a premier provider of diagnostic testing, information, and related services, serving clients both domestically and internationally. Its core business involves the development and provision of diverse diagnostic information services, such as routine, advanced clinical, and anatomic pathology testing. While primarily operating under the Quest Diagnostics brand, it also leverages specialized identities like AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum to reach a broad spectrum of clients. Its extensive client base includes patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and other direct healthcare entities. Delivery of these services is facilitated through a robust network comprising laboratories, patient service centers, in-office phlebotomists, call centers, and mobile health professionals including paramedics and nurses. Additionally, the company provides risk assessment services for the life insurance industry and offers comprehensive information technology solutions to healthcare organizations and clinicians.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- James E. Davis